RegeneRx Biopharmaceuticals, Inc. (RGRX) Receives Notice of Allowance From U.S. Patent Office for New Ophthalmic Indications
11/5/2012 9:43:51 AM
ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) today announced that it has received a Notice of Allowance of a U.S. patent for the use of Thymosin beta 4 (Tß4), certain fragments, isoforms, derivatives and analogues to treat patients with glaucoma and elevated intraocular pressure (IOP). Glaucoma refers to a group of eye conditions that lead to damage to the optic nerve. This nerve carries visual information from the eye to the brain. In most cases, damage to the optic nerve is due to increased pressure in the eye, known as intraocular pressure. Glaucoma is the second most common cause of blindness in the United States. The patent will expire in 2026.